New ultrasound technique could unlock secrets of placental health in pregnancy

NCT ID NCT06497959

Recruiting now Knowledge-focused Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study uses a special contrast dye (SonoVue) during ultrasound to look at blood flow in the placenta of pregnant women with fetal growth restriction. The goal is to better understand how the placenta works when the baby is not growing well. Thirty women who have already decided to end their pregnancy for medical reasons will take part, and the results may help doctors learn more about placental problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SonoVue (contrast agent for ultrasound)
What this could lead to: If successful, this could lead to better understanding of placental blood flow problems in fetal growth restriction, potentially guiding future treatments.
What could go wrong: This is a small, early-phase study (30 participants) focused on understanding, not treatment. The contrast agent's safety in pregnancy is still being studied, and results may not apply to all cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FETAL GROWTH RESTRICTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fetal growth restriction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FETAL GROWTH RESTRICTION

Contacts and locations

Locations

CHRU de NANCY
RECRUITING

Nancy, 54000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.